The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
In this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. Af...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2018-12-01
|
| Series: | Balkan Journal of Medical Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/bjmg-2018-0022 |
| _version_ | 1797760878348599296 |
|---|---|
| author | Demiray A Yaren A Karagenç N Bir F Demiray AG Karagür ER Tokgün O Elmas L Akça H |
| author_facet | Demiray A Yaren A Karagenç N Bir F Demiray AG Karagür ER Tokgün O Elmas L Akça H |
| author_sort | Demiray A |
| collection | DOAJ |
| description | In this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. After the extracted DNA was sequenced by pyrosequencing method, a total of 97 (32.0%) patients out of 300 were detected to carry an EGFR mutation and 75 (25.0%) patients out of 300 carried a KRAS mutation; 20 (6.6%) patients were detected to carry both of EGFR and KRAS mutations. The EGFR mutations were found to be statistically significant in female patients (48.0 women vs. 28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma (37.8 vs. squamous 26.8%). The overall rate of survival in patients receiving erlotinib therapy than in patients who did not. In patients without the KRAS mutation, the median overall survival rate was 161 ± 30 weeks with erlotinib therapy and 90 ± 13 weeks in patients without erlotinib therapy. In patients having KRAS mutation, the median overall survival was 98 ± 16 weeks with erlotinib therapy and 34 ± 16 weeks with no erlotinib therapy. In our study, we once again demonstrated that the presence of these mutations affected response to erlotinib therapy. The KRAS mutations negatively affected survival rate with and without erlotinib therapy. |
| first_indexed | 2024-03-12T19:04:53Z |
| format | Article |
| id | doaj.art-0d5a64cd0f4d4cec81b435f8025d41f8 |
| institution | Directory Open Access Journal |
| issn | 1311-0160 |
| language | English |
| last_indexed | 2024-03-12T19:04:53Z |
| publishDate | 2018-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Balkan Journal of Medical Genetics |
| spelling | doaj.art-0d5a64cd0f4d4cec81b435f8025d41f82023-08-02T06:19:00ZengSciendoBalkan Journal of Medical Genetics1311-01602018-12-01212212610.2478/bjmg-2018-0022bjmg-2018-0022The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapyDemiray A0Yaren A1Karagenç N2Bir F3Demiray AG4Karagür ER5Tokgün O6Elmas L7Akça H8Medical Biology Department, Pamukkale University, DenizliTurkeyMedical Oncology Department, Pamukkale University, DenizliTurkeyMedical Biology Department, Pamukkale University, DenizliTurkeyMedical Pathology Department, Pamukkale University School of Medicine, DenizliTurkeyMedical Oncology Department, Pamukkale University, DenizliTurkeyMedical Biology Department, Pamukkale University, DenizliTurkeyMedical Biology Department, Pamukkale University, DenizliTurkeyMedical Biology Department, Pamukkale University, DenizliTurkeyMedical Biology Department, Pamukkale University, DenizliTurkeyIn this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. After the extracted DNA was sequenced by pyrosequencing method, a total of 97 (32.0%) patients out of 300 were detected to carry an EGFR mutation and 75 (25.0%) patients out of 300 carried a KRAS mutation; 20 (6.6%) patients were detected to carry both of EGFR and KRAS mutations. The EGFR mutations were found to be statistically significant in female patients (48.0 women vs. 28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma (37.8 vs. squamous 26.8%). The overall rate of survival in patients receiving erlotinib therapy than in patients who did not. In patients without the KRAS mutation, the median overall survival rate was 161 ± 30 weeks with erlotinib therapy and 90 ± 13 weeks in patients without erlotinib therapy. In patients having KRAS mutation, the median overall survival was 98 ± 16 weeks with erlotinib therapy and 34 ± 16 weeks with no erlotinib therapy. In our study, we once again demonstrated that the presence of these mutations affected response to erlotinib therapy. The KRAS mutations negatively affected survival rate with and without erlotinib therapy.https://doi.org/10.2478/bjmg-2018-0022erlotinib therapyepidermal growth factor receptor (egfr)kirsten ras sarcoma (kras)non-small cell lung cancer (nsclc) |
| spellingShingle | Demiray A Yaren A Karagenç N Bir F Demiray AG Karagür ER Tokgün O Elmas L Akça H The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy Balkan Journal of Medical Genetics erlotinib therapy epidermal growth factor receptor (egfr) kirsten ras sarcoma (kras) non-small cell lung cancer (nsclc) |
| title | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy |
| title_full | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy |
| title_fullStr | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy |
| title_full_unstemmed | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy |
| title_short | The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy |
| title_sort | frequency of egfr and kras mutations in the turkish population with non small cell lung cancer and their response to erlotinib therapy |
| topic | erlotinib therapy epidermal growth factor receptor (egfr) kirsten ras sarcoma (kras) non-small cell lung cancer (nsclc) |
| url | https://doi.org/10.2478/bjmg-2018-0022 |
| work_keys_str_mv | AT demiraya thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT yarena thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT karagencn thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT birf thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT demirayag thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT karagurer thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT tokguno thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT elmasl thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT akcah thefrequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT demiraya frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT yarena frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT karagencn frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT birf frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT demirayag frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT karagurer frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT tokguno frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT elmasl frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy AT akcah frequencyofegfrandkrasmutationsintheturkishpopulationwithnonsmallcelllungcancerandtheirresponsetoerlotinibtherapy |